Scientists at the University of Michigan Medical School have discovered that a protein called cryopyrin responds to invading bacteria by triggering the activation of a powerful inflammatory molecule called IL-1beta, which signals the immune system to attack pathogens and induces fever to protect the body against infection.
The discovery could help scientists understand what causes autoimmune diseases like rheumatoid arthritis where the immune system attacks and destroys tissue in the patients body.
IL-1beta is a master regulator of infection, and its known to be involved in the development of rheumatoid arthritis, says Gabriel Nunez, MD, a professor of pathology at the U-M Medical School, who directed the research study. So its likely that these findings will apply to other autoimmune diseases, as well.
In a study being published Jan. 11 as an advance online publication in Nature, U-M scientists show, for the first time, that cryopyrin is activated by bacterial RNA and that it is essential to the cells ability to mount an effective defense against bacteria.
Found in the cytosol, or fluid inside cells, cryopyrin is a member of the NOD-LRR family of proteins, which protect cells against microbial infection. Defective cryopyrin is predicted to be associated with increased susceptibility to infection.
Small mutations in CIAS1 the human gene for cryopyrin are known to cause three rare autoinflammatory diseases: familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multiple-system inflammatory disease. People with these diseases produce uncontrolled amounts of IL-1beta and other inflammatory molecules. This causes them to have recurrent episodes of fever and to develop rashes often when they are exposed to cold temperatures.
Based on previous research with cell lines, scientists suspected that cryopyrin was an important link between the immune systems normal job of killing bacteria and the abnormal development of autoimmune diseases. But no one was sure exactly how cryopyrin was turned on in living animals or how it stimulated the immune response.
In previous research, the U-M team found that the single-point mutation in CIAS1 which causes autoinflammatory syndromes in people activates cryopyrin, even when there is no bacterial RNA present in the cell. The mutation fools the cell into producing the activated form of cryopyrin, even when bacteria arent there, Nunez says.
To decipher cryopyrins signal, Thirumala-Devi Kanneganti, PhD, a U-M post-doctoral research fellow in pathology, studied immune cells called macrophages and several strains of laboratory mice. One of these strains was unable to produce cryopyrin, because the CIAS1 gene had been removed.
Kanneganti exposed the macrophages and mice to bacterial RNA and to small synthetic molecules called R837 (Imiquimod) and R848 (Resiquimod). These adjuvant molecules activate the pro-inflammatory response in mice and are used as anti-tumor agents and to treat genital warts caused by a virus in human patients.
We found that cryopyrin was activated and the macrophages began secreting IL-1beta following stimulation with R837 or R848, Kanneganti says. Since the structure of these molecules is very similar to DNA or RNA, we believe the natural ligand, or activating molecule, for cryopyrin could be DNA or RNA.
In previous research, other scientists discovered a signaling pathway in which molecules called toll-like receptors on the cells surface recognize invading bacteria and activate the immune response. But U-M scientists found that cryopyrin uses a different signaling pathway. Activated cryopyrin triggers an enzyme called caspase-1, which splits the immature form of IL-1beta to produce the active form of the molecule. Once IL-1beta is activated, it can be secreted out of the cell where it binds to the IL-1beta receptor on other cells to trigger an immune response.
These two signaling pathways cooperate, Nunez explains. The toll-like receptor pathway recognizes bacteria outside the cell, while cryopyrin recognizes bacteria thats already in the cell. When a toll receptor on the membrane senses bacterial RNA, it activates a signaling pathway called NF-kappaB, which induces the production of IL-1beta. Cryopyrin does the same thing, but it works through caspase-1 to produce the active form of IL-1beta.
In her experiments, Kanneganti confirmed that the signaling pathway requires the presence of cryopyrin. Macrophages and mice that lacked the CIAS1 gene for cryopyrin were unable to generate an immune response when exposed to bacterial products.
The research was funded by the National Institute of Allergy and Infectious Diseases (NIAID). The University of Michigan has filed a patent application on this research technology.
Additional U-M collaborators on the study included Nesrin Ozoren, Mathilde Body-Malapel, Amal Amer, Jong-Hwan Park, Luigi Franchi and Joel Whitfield. Other collaborators were Winfried Barchet and Marco Colonna from the Washington University School of Medicine, Peter Vandenabeele from Belgiums Ghent University, John Bertin, Anthony Coyle and Ethan P. Grant from Millennium Pharmaceuticals and Shizuo Akira from Japans Osaka University.
Source: University of Michigan Health System   Â
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.